Late Stage Oncology MCDA Criteria Implementation Results in European Countries: Ukraine Focus

Speaker: Oresta Piniazhko, PhD
Senior lecturer
Danylo Halytsky Lviv National Medical University,
President of ISPOR Ukraine Chapter,
Member of Expert Committee of MoH of Ukraine

ISPOR 20th Annual European Congress: November 7th , 2017, Glasgow

Outline

- Study design background
- MCDA use and cooperation in CEE
- MCDA case study design
- Roadmap of HTA implementation in Ukraine
- Policy implications
- Current challenges and opportunities

Subject to discussion?

- current value assessment
- appraisal approaches of medical technologies using economic evaluation
- informing coverage decisions and improve efficiency in resource allocation

Source: Angelis A., Lange A., Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. The European Journal of Health Economics , 2017

Cooperation in ISPOR CEE Consortium: MCDA research

- ***Piniazhko O., Nemeth B.*** An analysis of the criteria used in existing or proposed MCDA models. ISPOR 21st Annual International Meeting Research Abstracts, May 21-25, 2016, Washington, DC, USA. Value in Health. 2016. 19(3): A106.
- ***Nemeth B., Piniazhko O.*** MCDA application in CEE: selection of the most important criteria based on examples. ISPOR 19th Annual European Congress, October 29-November 2, 2016, Vienna, Austria. Value in Health. 2016. PHP 180.
- ***Piniazhko O., Zalis'ka O., Zah V***. Eliciting payers preferences in CEE: results of MCDA case study. ISPOR 19th Annual European Congress, October 29-November 2, 2016, Vienna, Austria. Value in Health. 2016. PRM 59
- ***Piniazhko O., Nemeth B.*** Practical issues of determining weights for criteria to be used in an MCDA framework - based on a case-study. ISPOR 22nd Annual International Meeting Research Abstracts, May 20-24, 2017, Boston, MA, USA. Value in Health. 2017.

1st step: criteria analysis



Source: Piniazhko O., Nemeth B. An analysis of the criteria used in existing or proposed MCDA models. ISPOR 21st Annual International Meeting Research Abstracts, May 21-25, 2016, Washington, DC, USA. Value in Health. 2016. 19(3): A106.

Overall value of health technology: MCDA criteria selection for case study

Efficacy	**Is this NEW technology superior to standard of care and by how much?**	**Much lower-Lower-About the same as standard of care-Higher-Much higher**
Budg. Imp.	What is the budget impact of this NEW technology vs. standard of care, with the same number of patients treated? Is the inclusion of this drug sustainable from Insurance system perspective?	Significantly higher-Moderately higher-No difference-Moderately lower-Significantly lower
Safety	What is the safety profile (side effects and adverse effect) of this NEW technology vs. standard of care? (benefits of the drug exceeds its risks, while preserving appropriate standards for safety, especially when these patients have unmet needs - * same ethical and safety standards apply to rare and common disease drugs)	Much worse safety profile-Somewhat worse safety profile-The same safety profile as standard of care-Somewhat better safety profile-Much better safety profile
Unmet Need	To what extent patients receive provision in relation to their needs in the therapeutic area of NEW technology? Potential of the drugs to address unmet medical needs? Is there any available medication?	far below needs-below needs-met expectations-influential-extremely influential
Strategic	What are strategic/policy implications of reimbursement of NEW technology vs. standard of care? Political pressure to ensure that patients have access to high quality care, including effective drugs.	Major negative implications-Moderate negative implications-Neutral-Moderate positive implications-Major positive implications
Pt. Pref.	What is the patient preference towards this NEW technology vs. standard of care? Essential for obtaining values or weights indicating patients' trade-off preferences for health outcomes, health-care processes and treatment convenience features.	Not preferred at all-Slightly preferred-Moderately preferred-Very much preferred-Extremely preferred

Median weights on all criteria by all representatives: Ukraine case study



Physician on all criteria: Ukraine case study



Payer on all criteria: Ukraine case study



Pharmacist on all criteria: Ukraine case study



Implementation of HTA in Ukraine

- Project of National Drug Policy until 2025 in Ukraine
- Regulations on National list of Essential Medicines and Expert Committee

  (Order of MOH No.84 dated 12.02.2016)
- Regulation on the selection of drugs for inclusion on the National List of Essential Medicines

  (*Order of MOH No.1050 dated 07.10.2016)*
- National List of Essential Medicines

  (*Resolution of Cabinet of Ministers No. 180, dated 16.03.2017)*
- Changes of Regulation on the selection of drugs for inclusion on the National List of Essential Medicines

  (*Order of MOH No.885 dated 01.08.2017)*

HTA submissions: challenges and implications

- HTA submissions in Ukraine (including CEA and BIA) since 2017
- Assessment of submissions: 180 days by Expert Committee
- Decisions on inclusion on the list for national procurement programs and reimbursement: 1st results until 1st of July 2018

Order of MOH of Ukraine No.885 dated 01.08.2017

Legal framework of HTA in Ukraine, 2016-2017

- HTA for the inclusion of medicines on the list based on the applied evidence of:
  - quality
  - efficacy
  - effectiveness
  - safety
  - economic evaluation
- adhering to the Order of MOH No. 84 dated 11.02.2016 and Order of MOH No. 1050 dated 07.10.2016

Order of MOH of Ukraine No.885 dated 01.08.2017

Policy implications

- MCDA for priority settings
- HTA for innovative and high-priced medicines, financed by state budget
- Development of national PE guidelines in 2017:

  globalize the evidence and localize the decisions!
- Implementation of reimbursement programs for cardiovascular diseases, T2D, asthma since April 2017 in Ukraine→ expanding the list by new nosologies in 2017

15

Conclusions

- ✓High interest to participate and intention to implement the rational and consistent decisions by stakeholders in Ukraine
- ✓Criteria for BIA, unmet need have the highest value for payers
- ✓ Importantly, there is a necessity to implement international requirements to HTA, MCDA
- ✓ To improve the market access, medicines prescription and patients' health outcomes in Ukraine

16

Thank you!

Oresta Piniazhko *orestapb@gmail.com*